<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Next generation sequencing (NGS) technology has led to a burst of disease-relevant molecular information in a variety of <z:mp ids='MP_0002022'>lymphoid tumors</z:mp>, including <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">Waldenström macroglobulinemia</z:e>, hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and splenic marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Beside disclosing comprehensive catalogs of <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> and new insights into the genes that contribute to cellular transformation, NGS has also provided molecular clues useful for addressing a number of unmet clinical needs in the field of B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> management, including biomarkers for disease diagnosis and classification improvement (i.e. mutations of BRAF, MYD88 and NOTCH2), and new targets to be translated into therapeutic interventions (i.e. BCR, TLR, NOTCH, NF-κB and MAPK signaling pathways) </plain></SENT>
<SENT sid="2" pm="."><plain>This review summarizes the molecular lesions of signaling pathways that have been discovered in B-cell <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> by NGS studies </plain></SENT>
</text></document>